About the Program:
As many as 7 million people worldwide are infected with both HIV and HCV. Because of the potential consequences of HCV infection, clinicians who care for HCV/HIV co-infected patients face many complex treatment issues, including when to start treatment, which treatments to use, how long to treat patients, and which treatments can be safely combined in this population. In addition, they must remain abreast of rapidly changing information on the treatment of HCV/HIV co-infected patients. This program, "Managing HCV/HIV Co-Infection: What Clinicians Need to Know," is a series of six internet symposia, each covering a specific topic in the treatment of HCV/HIV co-infected patients. Each one-hour symposium will feature an interview of an expert in the field of HCV treatment, who will review and discuss the most essential information and data HIV clinicians need to know.
The second internet symposium is being brought to you from Boston, Massachusetts and will cover, "Treatment of Persons whom Prior DAA Therapy has Failed." This program will feature an interview with Susanna Naggie, MD, from Duke University by Mark Sulkowski, MD, from Johns Hopkins University. Dr. Naggie is a leading expert on the treatment and management of HCV/HIV co-infected patients.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV and HCV infection.
After completing this activity, the participant should be better able to:
- Appropriately screen patients for HCV to identify HCV/HIV co-infected patients in their practice
- Develop effective strategies for treating HCV in HIV-positive patients
- Apply the most recent information to the treatment of HCV/HIV co-infected patients to avoid drug-drug interactions, minimize adverse effects, and achieve successful outcomes
- Discuss research on HCV drugs in development to apply this information to ongoing treatment decisions
- Diagnose, manage and treat the social and psychiatric issues HCV/HIV co-infected patients may struggle with
Release Date: April 6, 2018
Expiration Date: April 6, 2019
Estimated time to complete the program: 1 hour
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Susanna Naggie, MD
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina
Joint Accreditation Statement:
||In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
European Continuous Medical Education Credit:
AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC®) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC®), therefore up to 1.0 ECMEC® Credits are available.
Disclosure of Conflicts of Interests:
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners
with high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial
relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the
content of these CME activities:
Susanna Naggie, MD:
- Contracted Research: Abbvie, BMS, Gilead, Janssen, Merck, Tacere
- Other (Non-commercial): IAS-USA, Mentor Meetings, Platform Q Health Inc., Practice Point Communications, Clinical Care Option, Vindico, Tacere
Mark Sulkowski, MD:
The PIM planners and managers, Trace Hutchison,
PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Shultz, RN, MSN, CHCP
have nothing to disclose.
- Contracted Research (to JHU): Abbvie, Gilead
- Consulting Fees: Abbvie, Gilead, Janssen, Merck
Instructions for Participation and Credit
There are no fees for participating and receved CME credit for this activity. During the period, April 6, 2018 through April 6, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 13236.
Upon registering and successfully completing the post-test with a score
of 70% or better and the activity evaluation, your certificate will be
made available immediately. Processing credit requests online will
reduce the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use
educational activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The planners of this activity
do not recommend the use of any agent outside of the labeled indications.
opinions expressed in the educational activity are those of the faculty and do
not necessarily represent the views of the planners. Please refer to the
official prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs